Synergy Pharmaceuticals Appoints Paul Eng, Ph.D., As Senior Vice President, Drug Development

Synergy Pharmaceuticals Appoints Paul Eng, Ph.D., As Senior Vice President, Drug Development

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the appointment of Paul Eng, Ph.D., as Senior Vice President, Drug Development. Dr. Eng will lead all clinical development operations for Synergy's pivotal phase 3 program with plecanatide in patients with irritable bowel syndrome with constipation (IBS-C). 

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.